Pharmacokinetics of pipecuronium in infants, children and adults

E. Tassonyi, J. F. Pittet, C. N. Schopfer, J. C. Rouge, G. Gemperle, O. H G Wilder-Smith, D. R. Morel

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In order to explain the reported shorter clinical duration of action of cumulative ED95 of pipecuronium in infants as compared to children or adults, the pharmacokinetic profiles of pipecuronium were compared in infants (n=6; mean age 6.8 months; mean weight 7.3 kg) in children (n=6; mean age 4.6 years; mean weight 19.2 kg) and in adults (n=7; mean age 42 years; mean weight 58.2 kg). Equipotent doses (2 × ED95) of pipecuronium were injected i.v. as single bolus and arterial blood was sampled for 4-5 h. Pipecuronium was quantified by complex formation with [125I]-labelled rose bengal. Pharmacokinetic parameters were calculated using a two-compartment open model. The median for the distribution half-life of pipecuronium was 2.54 min (interquartile range: 1.0-2.5 min) in infants and 2.04 min (0.26-2.04 min) in children; both were significantly shorter than in adults (5.75 [3.7-9.7] min). The plasma clearance of pipecuronium was significantly decreased in infants (1.50 [0.6-1.5] ml.min-1.kg-1;P-1. kg-1, respectively). The total volume of distribution was similar in all three groups. We conclude that the pharmacokinetic features of pipecuronium are age-dependent: differences as compared to adults consisted of a faster distribution in both infants and children and a slower elimination in infants. The pharmacokinetic profile of pipecuronium does not explain the faster recovery from neuromuscular blockade in infants as compared to children. Because of the low total plasma clearance in infants, pipecuronium dosage should be carefully monitored to avoid accumulation and prolonged paralysis.

Original languageEnglish
Pages (from-to)203-208
Number of pages6
JournalEuropean Journal of Drug Metabolism and Pharmacokinetics
Volume20
Issue number3
DOIs
Publication statusPublished - Sep 1995

Fingerprint

Pipecuronium
Pharmacokinetics
Weights and Measures
Rose Bengal
Neuromuscular Blockade
Paralysis
Half-Life

Keywords

  • adults
  • Age factors
  • children
  • infants
  • neuromuscular relaxants
  • pharmacokinetics
  • pipecuronium bromide

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Tassonyi, E., Pittet, J. F., Schopfer, C. N., Rouge, J. C., Gemperle, G., Wilder-Smith, O. H. G., & Morel, D. R. (1995). Pharmacokinetics of pipecuronium in infants, children and adults. European Journal of Drug Metabolism and Pharmacokinetics, 20(3), 203-208. https://doi.org/10.1007/BF03189671

Pharmacokinetics of pipecuronium in infants, children and adults. / Tassonyi, E.; Pittet, J. F.; Schopfer, C. N.; Rouge, J. C.; Gemperle, G.; Wilder-Smith, O. H G; Morel, D. R.

In: European Journal of Drug Metabolism and Pharmacokinetics, Vol. 20, No. 3, 09.1995, p. 203-208.

Research output: Contribution to journalArticle

Tassonyi, E, Pittet, JF, Schopfer, CN, Rouge, JC, Gemperle, G, Wilder-Smith, OHG & Morel, DR 1995, 'Pharmacokinetics of pipecuronium in infants, children and adults', European Journal of Drug Metabolism and Pharmacokinetics, vol. 20, no. 3, pp. 203-208. https://doi.org/10.1007/BF03189671
Tassonyi, E. ; Pittet, J. F. ; Schopfer, C. N. ; Rouge, J. C. ; Gemperle, G. ; Wilder-Smith, O. H G ; Morel, D. R. / Pharmacokinetics of pipecuronium in infants, children and adults. In: European Journal of Drug Metabolism and Pharmacokinetics. 1995 ; Vol. 20, No. 3. pp. 203-208.
@article{7ad96e7543754607a20c7d6e5def7ca0,
title = "Pharmacokinetics of pipecuronium in infants, children and adults",
abstract = "In order to explain the reported shorter clinical duration of action of cumulative ED95 of pipecuronium in infants as compared to children or adults, the pharmacokinetic profiles of pipecuronium were compared in infants (n=6; mean age 6.8 months; mean weight 7.3 kg) in children (n=6; mean age 4.6 years; mean weight 19.2 kg) and in adults (n=7; mean age 42 years; mean weight 58.2 kg). Equipotent doses (2 × ED95) of pipecuronium were injected i.v. as single bolus and arterial blood was sampled for 4-5 h. Pipecuronium was quantified by complex formation with [125I]-labelled rose bengal. Pharmacokinetic parameters were calculated using a two-compartment open model. The median for the distribution half-life of pipecuronium was 2.54 min (interquartile range: 1.0-2.5 min) in infants and 2.04 min (0.26-2.04 min) in children; both were significantly shorter than in adults (5.75 [3.7-9.7] min). The plasma clearance of pipecuronium was significantly decreased in infants (1.50 [0.6-1.5] ml.min-1.kg-1;P-1. kg-1, respectively). The total volume of distribution was similar in all three groups. We conclude that the pharmacokinetic features of pipecuronium are age-dependent: differences as compared to adults consisted of a faster distribution in both infants and children and a slower elimination in infants. The pharmacokinetic profile of pipecuronium does not explain the faster recovery from neuromuscular blockade in infants as compared to children. Because of the low total plasma clearance in infants, pipecuronium dosage should be carefully monitored to avoid accumulation and prolonged paralysis.",
keywords = "adults, Age factors, children, infants, neuromuscular relaxants, pharmacokinetics, pipecuronium bromide",
author = "E. Tassonyi and Pittet, {J. F.} and Schopfer, {C. N.} and Rouge, {J. C.} and G. Gemperle and Wilder-Smith, {O. H G} and Morel, {D. R.}",
year = "1995",
month = "9",
doi = "10.1007/BF03189671",
language = "English",
volume = "20",
pages = "203--208",
journal = "European Journal of Drug Metabolism and Pharmacokinetics",
issn = "0378-7966",
publisher = "Springer Paris",
number = "3",

}

TY - JOUR

T1 - Pharmacokinetics of pipecuronium in infants, children and adults

AU - Tassonyi, E.

AU - Pittet, J. F.

AU - Schopfer, C. N.

AU - Rouge, J. C.

AU - Gemperle, G.

AU - Wilder-Smith, O. H G

AU - Morel, D. R.

PY - 1995/9

Y1 - 1995/9

N2 - In order to explain the reported shorter clinical duration of action of cumulative ED95 of pipecuronium in infants as compared to children or adults, the pharmacokinetic profiles of pipecuronium were compared in infants (n=6; mean age 6.8 months; mean weight 7.3 kg) in children (n=6; mean age 4.6 years; mean weight 19.2 kg) and in adults (n=7; mean age 42 years; mean weight 58.2 kg). Equipotent doses (2 × ED95) of pipecuronium were injected i.v. as single bolus and arterial blood was sampled for 4-5 h. Pipecuronium was quantified by complex formation with [125I]-labelled rose bengal. Pharmacokinetic parameters were calculated using a two-compartment open model. The median for the distribution half-life of pipecuronium was 2.54 min (interquartile range: 1.0-2.5 min) in infants and 2.04 min (0.26-2.04 min) in children; both were significantly shorter than in adults (5.75 [3.7-9.7] min). The plasma clearance of pipecuronium was significantly decreased in infants (1.50 [0.6-1.5] ml.min-1.kg-1;P-1. kg-1, respectively). The total volume of distribution was similar in all three groups. We conclude that the pharmacokinetic features of pipecuronium are age-dependent: differences as compared to adults consisted of a faster distribution in both infants and children and a slower elimination in infants. The pharmacokinetic profile of pipecuronium does not explain the faster recovery from neuromuscular blockade in infants as compared to children. Because of the low total plasma clearance in infants, pipecuronium dosage should be carefully monitored to avoid accumulation and prolonged paralysis.

AB - In order to explain the reported shorter clinical duration of action of cumulative ED95 of pipecuronium in infants as compared to children or adults, the pharmacokinetic profiles of pipecuronium were compared in infants (n=6; mean age 6.8 months; mean weight 7.3 kg) in children (n=6; mean age 4.6 years; mean weight 19.2 kg) and in adults (n=7; mean age 42 years; mean weight 58.2 kg). Equipotent doses (2 × ED95) of pipecuronium were injected i.v. as single bolus and arterial blood was sampled for 4-5 h. Pipecuronium was quantified by complex formation with [125I]-labelled rose bengal. Pharmacokinetic parameters were calculated using a two-compartment open model. The median for the distribution half-life of pipecuronium was 2.54 min (interquartile range: 1.0-2.5 min) in infants and 2.04 min (0.26-2.04 min) in children; both were significantly shorter than in adults (5.75 [3.7-9.7] min). The plasma clearance of pipecuronium was significantly decreased in infants (1.50 [0.6-1.5] ml.min-1.kg-1;P-1. kg-1, respectively). The total volume of distribution was similar in all three groups. We conclude that the pharmacokinetic features of pipecuronium are age-dependent: differences as compared to adults consisted of a faster distribution in both infants and children and a slower elimination in infants. The pharmacokinetic profile of pipecuronium does not explain the faster recovery from neuromuscular blockade in infants as compared to children. Because of the low total plasma clearance in infants, pipecuronium dosage should be carefully monitored to avoid accumulation and prolonged paralysis.

KW - adults

KW - Age factors

KW - children

KW - infants

KW - neuromuscular relaxants

KW - pharmacokinetics

KW - pipecuronium bromide

UR - http://www.scopus.com/inward/record.url?scp=0028790352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028790352&partnerID=8YFLogxK

U2 - 10.1007/BF03189671

DO - 10.1007/BF03189671

M3 - Article

C2 - 8751042

AN - SCOPUS:0028790352

VL - 20

SP - 203

EP - 208

JO - European Journal of Drug Metabolism and Pharmacokinetics

JF - European Journal of Drug Metabolism and Pharmacokinetics

SN - 0378-7966

IS - 3

ER -